Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed acute symptomatic DVT~* Written informed consent~Exclusion Criteria:~* Legal lower age limitations~* Patients with symptomatic pulmonary embolism~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT~* Other indication for VKA than DVT~* More than 36 hours before the treatment with therapeutic dosages of low molecular weight heparin or initiation of VKA treatment prior to randomization~* Participation in another pharmacotherapeutic study within the prior 30 days~* Creatinine clearance \<10mL/min, severe hepatic disease or bacterial endocarditis~* Life expectancy \<3 Months~* Active bleeding or high risk for bleeding~* Uncontrolled hypertension: systolic blood pressure \>180 mm Hg and diastolic blood pressure \>110 mm Hg.~* Pregnancy or childbearing potential without proper contraceptive measures~* Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin (UFH), enoxaparin, or tinzaparin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).